Is neuroimmunomodulation a future therapeutic approach for sepsis?

International Immunopharmacology

Volumn 10, Issue 1, 2010, Pages 9-17

  Kumar, V ^a   Sharma, A ^b  

^a PANJAB UNIVERSITY   (India)

^b DR Y S PARMAR UNIVERSITY OF HORTICULTURE AND FORESTRY   (India)

Author keywords

HPA axis; Neuroimmunomodulation; Peripheral nervous system; Sepsis; Sympathetic nervous system

Indexed keywords

2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ANTALARMIN; CLONIDINE; CORTICOTROPIN; DEXMEDETOMIDINE; GHRELIN; MELANOCORTIN; METHOETRAMINE; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR; NEOSTIGMINE; NICOTINE; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA7; NICOTINIC RECEPTOR; PHYSOSTIGMINE; SEMAPIMOD; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; CHOLINERGIC SYSTEM; DIET THERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEMORRHAGIC SHOCK; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; LIPID DIET; MORTALITY; NERVE STIMULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; VAGUS NERVE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; MULTIPLE ORGAN FAILURE; NEUROIMMUNOMODULATION; PITUITARY-ADRENAL SYSTEM; RECEPTORS, ADRENERGIC; SEPSIS; VAGUS NERVE STIMULATION;

EID: 73149120717     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.10.003     Document Type: Review

References (103)

1. Abraham E., Matthay M.A., Dinarello C.A., Vincent J.L., Cohen J., Opal S.M., et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: a reevaluation. Crit Care Med 28 (2000) 232-235
2. Matot I., and Sprung C.L. Definitions of sepsis. Intensive Care Med 27 (2001) 83-89
3. Ulloa L., and Tracey K.J. The 'cytokine profile': a code for sepsis. Trends Immunol 11 (2005) 56-63
4. Felty A., and Keefer C. Bacillus coli sepsis. JAMA 82 (1924) 1430-1433
5. Danai P.A., Sinha S., Moss M., Haber M.J., and Martin G.S. Seasonal variation in the epidemiology of sepsis. Crit Care Med 35 (2007) 410-415
6. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
7. Kumar V., Harjai K., and Chhibber S. A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055 induced sepsis. J Chemother 21 2 (2009) 105-110
8. Cohen J. The immunopathogenesis of sepsis. Nature 420 (2002) 885-891
9. Kumar V., and Sharma A. Innate immunity in sepsis pathogenesis and its modulation: new immunomodulatory targets revealed. J Chemother 20 (2008) 79-90
10. Riedemann N.C., Guo R.-F., and Ward P.A. Novel strategies for the treatment of sepsis. Nat Med 9 5 (2003) 517-524
11. Sternberg E.M. Neural regulator of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 6 4 (2006) 318-328
12. Woiciechowsky C., Schoning B., Lanksch W.R., Volk H.-D., and Docke W.D. Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J Mol Med 77 (1999) 769-780
13. Dantzer R., O'Connor J.C., Freund G.C., Johnson R.W., and Kelley K.W. From inflammation to sickness and depression: when the immune subjugates the brain. Nat Rev Neurosci (2007) 10.1038/nrn2297
14. Ebersoldt M., Sharshar T., and Annane D. Sepsis associated delirium. Intensive Care Med 33 (2007) 941-950
15. Shepherd A.J., Downing J.E.G., and Miyan J.A. Without nerves, immunology remains incomplete - in vivo veritas. Immunology 116 (2005) 145-163
16. Annane D. Hippocampus: a future target for sepsis treatment. Intensive Care Med 10 (2009) 1395-1396
17. Munford R.S., and Tracey K.J. Is severe sepsis a neuroendocrine disease. Mol Med 8 8 (2002) 437-442
18. John C.D., and Buckingham J.C. Cytokines: regulation of hypothalamo-pituitary-adrenocortical axis. Curr Opin Pharmacol 3 (2003) 378-384
19. Turnbull A.V., and Rivier C.L. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 79 (1999) 171
20. Chesnokova V., and Melmed S. Mini review: neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology 143 (2002) 1571-1574
21. Bornstein S.R., and Chrousos G.P. Adrenocorticotrophin (ACTH)- and non-ACTH-mediated regulation of adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 84 (1998) 1729-1736
22. Munford R.S., and Levine J.D. The crucial role of the systemic responses in the innate (non-adaptive) host defense. J Endotoxin Res 7 (2001) 327-332
23. Kapcala L.P., Chautard T., and Eskay R.L. The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress. Ann N Y Acad Sci 771 (1995) 419-437
24. Besedovsky H., del R.A., Sorkin E., and Dinarello C.A. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233 (1986) 652-654
25. Elenkov I.J., and Chrousos G.P. Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab 10 (1999) 359-368
26. Eskandari F., Webster J.I., and Sternberg E.M. Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther 5 (2003) 251-265
27. Elenkov I.J., Wilder R.L., Chrousos G.P., and Vizi E.S. The sympathetic nerve - an integrative interface between two super systems: the brain and the immune system. Pharmacol Rev 52 (2000) 595-638
28. Weihe E., Nohr D., Michel S., Muller S., Zentel H.J., Fink T., et al. Molecular anatomy of the neuro-immune connection. Int J Neurosci 59 (1991) 1-23
29. Madden K.S., Sanders V.M., and Felten D.L. Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu Rev Pharmacol Toxicol 35 (1995) 417-448
30. Woiciechowsky C., Ruprecht S., Docke W.-D., and Volk H.-D. Role of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in brain-mediated compensatory anti-inflammatory response. Biomed Rev 11 (2000) 29-38
31. Elenkov I.J., Kovacs K., Kiss J., Bertok L., and Vizi E.S. Lipopolysaccharide is able to bypass corticotrophin-releasing factor in affecting plasma ACTH and corticosterone levels: evidence from rats with lesions of the paraventricular nucleus. J Endocrinol 133 (1992) 231-236
32. Dunn A.J., Wang J., and Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 461 (1999) 117-127
33. Zhang J.J., Swiergiel A.H., Palamarchouk V.S., and Dunn A.J. Intracerebroventricular infusion of CRF increases extracellular concentrations of norepinephrine in the hippocampus and cortex as determined by in vivo voltammetry. Brain Res Bull 47 (1998) 277-284
34. Berkenbosch F., de Goeij D., del Rey A.E., and Besedovsky H.O. Neuroendocrine, sympathetic and metabolic responses induced by interleukin-1. Neuroendocrinology 50 (1989) 570-576
35. Katafuchi T., Hori T., and Take S. Central administration of interferon-alpha enhances rat sympathetic nerve activity to the spleen. Neurosci Lett 125 (1991) 37-40
36. Shimizu N., Hori T., and Nakane H. An interleukin-1beta-induced noradrenaline release in the spleen is mediated by brain corticotropin-releasing factor: an in vivo microdialysis study in conscious rats. Brain Behav Immun 8 (1994) 14-23
37. Maier S.F., Goehler L.E., Fleshner M., and Watkins L.R. The role of the vagus nerve in cytokine-to-brain communication. Ann N Y Acad Sci 840 (1998) 289-300
38. Miksa M., Wu R., Zhou M., and Wang P. Sympathetic excitotoxicity in sepsis: proinflammatory priming of macrophages by norepinephrine. Front Biosci 10 (2005) 2217-2229
39. Yang S., Koo D.J., Zhou M., Chaudry I.H., and Wang P. Gut-derived norepinephrine plays a critical role in producing hepatocellular dysfunction during early sepsis. Am J Physiol Gastrointest Liver Physiol 279 (2000) G1274-1281
40. Bergmann M., and Sautner T. Immunomodulatory effects of vasoactive catecholamines. Wien Klin Wochenschr 114 (2002) 752-761
41. Hahn P.Y., Wang P., Tait S.M., Ba Z.F., Reich S.S., and Chaudry I.H. Sustained elevation in circulating catecholamine levels during polymicrobial sepsis. Shock 4 (1995) 269-273
42. Zhou M., Simms H.H., and Wang P. Increased gut-derived norepinephrine release in sepsis: up-regulation of intestinal tyrosine hydroxylase. Biochem Biophys Acta 1689 (2004) 212-218
43. Baltazar G., and Duarte E.P. Differential expression of syntaxin 1A and 1B by noradrenergic and adrenergic chromaffin cells. Neurochem Res 28 (2003) 1453-1457
44. Sung U., Apparsundaram S., Galli A., Kahlig K.M., Savchenko V., Schroeter S., et al. A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J Neurosci 23 (2003) 1697-1709
45. Masson J., Sagne C., Hamon M., and Mestikawy S.E. Neurotransmitter transporters in the central nervous system. Pharmacol Rev 51 (1999) 439-464
46. Spengler R.N., Allen R.M., Remick D.G., Strieter R.M., and Kunkel S.L. Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol 145 (1990) 1430-1434
47. Heijnen C.J., Rouppe van der V.C., Wulffraat N., van der N.J., Kuis W., and Kavelaars A. Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. J Neuroimmunol 71 (1996) 223-226
48. Panina-Bordignon P., Mazzeo D., Lucia P.D., D'Ambrosio D., Lang R., Fabbri L., et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 100 (1997) 1513-1519
49. Hasko G., Nemeth Z.H., Szabo C., Zsilla G., Salzman A.L., and Vizi E.S. Isoproterenol inhibits IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages. Brain Res Bull 45 (1998) 183-187
50. Siegmund B., Eigler A., Hartmann G., Hacker U., and Endres S. Adrenaline enhances LPS-induced IL-10 synthesis: evidence for protein kinase A-mediated pathway. Int J Immunopharmacol 20 (1998) 57-69
51. Hasko G., Shanley T.P., Egnaczyk G., Nemeth Z.H., Salzman A.L., Vizi E.S., et al. Exogenous and endogenous catecholamines inhibit the production of macrophage inflammatory protein (MIP) 1 alpha via a beta adrenoceptor mediated mechanism. Br J Pharmacol 125 (1998) 1297-1303
52. Gallowitsch-Puerta M., and Pavlov V.A. Neuro-immune interactions via the cholinergic anti-inflammatory pathway. Life Sci (2007) 10.1016/j.1fs.2007.01.002
53. Watkins L.R., and Maier S.F. Implications of immune-to-brain communication for sickness and pain. Proc Natl Acad Sci USA 96 (1999) 7710-7713
54. Goehler L.E., Gaykema R.P.A., Hansen M.K., Anderson K., Maier S.F., and Watkins L. Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton Neurosci 85 (2000) 49-59
55. Pavlov A.V., Wang H., Czura C.J., Friedman S.G., and Tracey K.J. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med 9 5-8 (2003) 125-134
56. Rothwell N.J., and Luheshi G.N. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 23 (2000) 618-625
57. Laflamme N., Lacroix S., and Rivest S. An essential role of interleukin-1β in mediating NF-kB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J Neurosci 19 (1999) 10923-10930
58. Tracey K.J. The inflammatory reflex. Nature 420 (2002) 853-859
59. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 6785 (2000) 458-462
60. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421 6921 (2003) 384-388
61. De Jonge W.J., van der Zanden E.P., The F.O., Bijlsma M.F., van Westerloo D.J., Bennink R.J., et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-Stat3 signaling pathway. Nat Immunol 6 (2005) 844-851
62. Huston J.M., Ochani M., Rosas-Ballina M., Liao H., Ochani K., Pavlov V.A., et al. Splenectomy inactivates the cholinergic anti-inflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 203 7 (2006) 1623-1628
63. Ghia J.E., Blennerhassett P., Kumar-Ondiveeran H., Verdu E.F., and Collins S.M. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology 131 4 (2006) 1122-1130
64. Bernik T.R., Friedman S.G., Ochani M., DiRaimo R., Ulloa L., Yang H., et al. Pharmacological stimulation of the cholinergic anti-inflammatory pathway. J Exp Med 195 (2002) 781-789
65. Guarini S., Altavilla D., Cainazzo M.M., Giuliani D., Bigiani A., Marini H., et al. Efferent vagal nerve stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock. Circulation 107 (2003) 1189-1194
66. Wang H., Liao H., Ochani M., Justiniani M., Lin X., Yang L., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10 (2004) 1216-1221
67. Grando S.A., Kawashima K., and Wessler I. Introduction: the non-neuronal cholinergic system in humans. Life Sci 72 18-19 (2003) 2009-2012
68. de la Torre E., Davel L., Jasnis M.A., Goton T., de Lustig E.S., and Sales M.E. Muscarinic receptors participation in angiogenic response induced by macrophages from mammary adenocarcinoma-bearing mice. Breast Cancer Res 7 (2005) R345-R352
69. Saeed R.W., Varma S., Peng-Nemeroff T., Sherry B., Balakhaneh D., Huston J., et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 201 7 (2005) 1113-1123
70. Kawashima K., Yoshikawa K., Fujii Y., and Moriwaki Y. Expression and function of genes encoding cholinergic components in murine immune cells. Life Sci 80 (2007) 2314-2319
71. Guarini S., Cainazzo M.M., Giuliani D., Mioni C., Altavilla D., Marini H., et al. Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway. Cardiovasc Res 63 (2004) 357-365
72. Gallowitsch-Puerta M., and Tracey K.J. Immunologic role of the cholinergic anti-inflammatory pathway and the nicotinic acetylcholine α7 receptor. Ann N Y Acad Sci 1062 (2005) 1-11
73. Saito K., Yoshioka M., Kohya T., and Kitabatake A. Involvement of muscarinic M1 receptor in the central pathway of the serotonin-induced Bezold Jarisch reflex in rats. J Auton Nerv Syst 49 (1994) 64-68
74. Li Y., Wu X., Zhu J., Yan J., and Owyang C. Hypothalamic regulation of pancreatic secretion is mediated by central cholinergic pathways in the rat. J Physiol 552 (2003) 571-587
75. Pavlov V.A., Ochani M., Gallowitsch-Puerta M., Ochani K., Huston J.M., Czura C.J., et al. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci USA 103 13 (2006) 5219-5233
76. Stillman M.J., Shukitt-Hale B., Kong R.M., Levy A., and Lieberman H.R. Elevation of hippocampal extracellular acetylcholine levels by methoctramine. Brain Res Bull 32 (1993) 385-389
77. Quirion R., Wilson A., Rowe W., Aubert I., Richard J., Doods H., et al. Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. J Neurosci 15 (1995) 1455-1462
78. Stillman M.J., Shukitt-Hale B., Galli R.L., Levy A., and Lieberman H.R. Effects of M2 antagonists on in vivo hippocampal acetylcholine levels. Brain Res Bull 41 (1996) 221-226
79. Borovikova L.V., Ivanova S., Nardi D., Zhang M., Yang H., Ombrellino M., et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci 85 (2000) 141-147
80. Pavlov V.A., and Tracey K.J. The cholinergic anti-inflammatory pathway. Brain Behav Immun 19 (2005) 493-499
81. Pavlov V.A., Ochani M., Yang L.-H., Gallowitsch-Puerta M., Ochani K., Lin X., et al. Selective α7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 35 4 (2007) 1139-1144
82. Hofer S., Eisenbech C., Lukic I.K., Schneider L., Bonde K., Brueckmann M., et al. Pharmocolgic cholineaterase inhibition improves survival in experimental sepsis. Crit Care Med 36 2 (2008) 404-408
83. Luyer M.D., Willem J., Greve M., Hadfoune M., Jacobs J.A., Dejong C.H., et al. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med 202 (2005) 1023-1029
84. van Westerloo D.J., Giebelen I.A., Florquin S., Daalhuisen J., Bruno M.J., de Vos A.F., et al. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis 191 (2005) 2138-2148
85. van Westerloo D.J., Giebelen I.A., Meijers J.C., Daalhuisen J., de Vos A.F., Levi M., et al. Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats. J Thromb Haemost 4 (2006) 1997-2002
86. Lipton J.M., and Catania A. Anti-inflammatory actions of the neuroimmunomodulator α-MSH. Immunol Today 18 (1997) 140-145
87. Taylor A.W. The immunomodulating neuropeptide α-melanocyte-stimulating hormone (α-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. J Neuroimmunol 162 (2005) 43-50
88. Agelaki S., Tsatsanis C., Gravanis A., and Margioris A.N. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect Immun 70 (2002) 6068-6074
89. Webster E.L., Lewis D.B., Torpy D.J., Zachman E.K., Rice K.C., and Chrousos G.P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotrophin releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137 (1996) 5747-5750
90. Hommes D., van den Blink B., Plasse T., Bartelsman J., Xu C., Macpherson B., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122 (2002) 7-14
91. Miksa M, Das P, Zhou M, Wu R, Dong W, Ji Y, Goyert SM, Ravikumar TS, Wang P. Pivotal Role of the a2A-Adrenoceptor in Producing Inflammation and Organ Injury in a Rat Model of Sepsis. PLoS One 2009;4(5):e5504. doi:10.1371/journal.pone.0005504.
92. Basa N.R., Wang L., Arteaga J.R., Heber D., Livingston E.H., and Tache Y. Bacterial lipopolysaccharide shifts fasted plasma ghrelin to postprandial levels in rats. Neurosci Lett 343 (2003) 25-28
93. Hataya Y., Akamizu T., Hosoda H., Kanamoto N., Moriyama K., Kangawa K., et al. Alterations of plasma ghrelin levels in rats with lipopolysaccharide-induced wasting syndrome and effects of ghrelin treatment on the syndrome. Endocrinology 144 (2003) 5365-5371
94. Wu R., Zhou M., Cui X., Simms H.H., and Wang P. Upregulation of cardiovascular ghrelin receptor occurs in the hyperdynamic phase of sepsis. Am J Physiol Heart Circ Physiol 287 (2004) H1296-H1302
95. Wu R, Dong W, Zhou M, Cui X, Hank Simms H, Wang P. Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc Res 2005;68(2):318-26.
96. Wu R., Dong W., Cui X., Zhou M., Simms H.H., Ravikumar T.S., et al. Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg 245 (2007) 480-486
97. Wu R., Dong W., Zhou M., Zhang F., Marini C.P., Ravikumar T.S., et al. Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am J Respir Crit Care Med 176 (2007) 805-813
98. Chorny A., Anderson P., Gonzalez-Rey E., and Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J immunol 180 (2008) 8369-8377
99. Wu R., Dong W., Qiang X., Wang H., Blau S., Ravikumar T.S., et al. Orexigenic hormone ghrelin ameliorates gut barrier dysfunction in sepsis in rats. Crit Care Med (Jun 15 2009) PMID: 19531942
100. Chen Q.H., Haywood J.R., and Toney G.M. Sympathoexcitation by PVN-injected bicuculline requires activation of excitatory amino acid receptors. Hypertension 42 (2003) 725-731
101. Hamano N., Inada T., Iwata R., Asai T., and Shingu K. The a2-adrenergic receptor antagonist yohimbine improves endotoxin-induced inhibition of gastrointestinal motility in mice. Br J Anaes 98 4 (2007) 484-490
102. Miksa M., Das P., Zhou M., Wu R., Dong W., Ji Y., et al. Pivotal role of the a2A-Adrenoceptor in producing inflammation and organ injury in a rat model of sepsis. PLoS ONE 4 5 (2009) e5504 10.1371/journal.pone.0005504
103. Hofer S., Steppan J., Wagner T., Funke B., Lichtenstern C., Martin E., et al. Central sympatholytics prolong survival in experimental sepsis. Crit Care 13 (2009) R11 10.1186/cc7709